Ophélia Godin

Ophélia Godin

Auto-generated profile, based on publicly available information

Ophélia Godin

Fondation Fondamental Créteil France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in Bipolar Disorders
Verified
Journal Article
Open access
BSBalwinder Singh
Balwinder Singh
AYAnastasia K. Yocum
Anastasia K. Yocum
RSRebecca Strawbridge
Rebecca Strawbridge
KBKatherine E. Burdick
Katherine E. Burdick
CMCaitlin E. Millett
Caitlin E. Millett
MFMark A. Frye
Mark A. Frye
Objectives: To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic treatment patterns in multiple cohorts of well‐characterized individuals with BD in North America, Europe, and Australia.Methods: Data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities were provided from each participating cohort. Individual site and regional pooled proportional meta‐analyses with generalized linear mixed methods were conducted to identify prescription patterns.Results: This study included 10,351 individuals from North America (n = 3985), Europe (n = 3822), and Australia (n = 2544). Overall, participants were predominantly female (60%) with BD‐I (60%; vs. BD‐II = 33%). Cross‐sectionally, mood‐stabilizing anticonvulsants (44%), second‐generation antipsychotics (42%), and antidepressants (38%) were the most prescribed medications. Lithium was prescribed in 29% of patients, primarily in the Australian (31%) and European (36%) cohorts. First‐generation antipsychotics were prescribed in 24% of the European versus 1% in the North American cohort. Antidepressant prescription rates were higher in BD‐II (47%) compared to BD‐I (35%). Major limitations were significant differences among cohorts based on inclusion/exclusion criteria, data source, and time/year of enrollment into cohort.Conclusions: Mood‐stabilizing anticonvulsants, second‐generation antipsychotics, and antidepressants were the most prescribed medications suggesting prescription patterns that are not necessarily guideline concordant. Significant differences exist in the prescription practices across different geographic regions, especially the underutilization of lithium in the North American cohorts and the higher utilization of first‐generation antipsychotics in the European cohorts. There is a need to conduct future longitudinal studies to further explore these differences and their impact on outcomes, and to inform and implement evidence‐based guidelines to help improve treatment practices in BD.

28 October 2014 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
OGOphélia Godin
Ophélia Godin
FCfor the FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators
for the FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators
BEBruno Etain
Bruno Etain
CHChantal Henry
Chantal Henry
TBThierry Bougerol
Thierry Bougerol
MLMarion Leboyer
Marion Leboyer
The aim of this study was to estimate the prevalence of metabolic syndrome (MetS) and its components in a cohort of French patients with bipolar disorder; determine correlations with sociodemographic, clinical, and treatment-related factors; and investigate the gap between optimal care and effective care of the treated patients. 654 bipolar disorder patients from the FACE-BD cohort were included from 2009 to 2012. Sociodemographic and clinical characteristics, lifestyle information, and data on antipsychotic treatment and comorbidities were collected, and a blood sample was drawn. The Structured Clinical Interview for DSM-IV Axis I Disorders was used to confirm the diagnosis of bipolar disorder. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria. 18.5% of individuals with bipolar disorder met criteria for MetS. Two-thirds of bipolar disorder patients did not receive adequate treatment for MetS components. Multivariate analysis showed that risk of MetS in men was nearly twice that in women (OR = 1.9; 95% CI, 1.0-3.8), and older patients had a 3.5 times higher risk (95% CI, 1.5-7.8) of developing MetS than patients under the age of 35 years. Moreover, patients receiving antipsychotic treatment had a 2.3 times increased risk (95% CI, 1.2-3.5) of having MetS, independent of other potential confounders. The prevalence of MetS is high in bipolar disorder patients, and there was considerable undertreatment of the components of MetS in this population. The prevention and treatment of cardiovascular diseases in these patients should be assessed systematically. The findings highlight the need for integrated care, with more interaction and coordination between psychiatrists and primary care providers.

1 October 2009 in Stroke
Verified
Journal Article
Closed access
PDF file
OGOphélia Godin
Ophélia Godin
CTChristophe Tzourio
Christophe Tzourio
PMPauline Maillard
Pauline Maillard
AAAnnick Alpérovitch
Annick Alpérovitch
BMBernard Mazoyer
Bernard Mazoyer
CDCarole Dufouil
Carole Dufouil
Background and Purpose— The relationship between white matter lesions (WMLs) and the apolipoprotein E genotype has been controversial from cross-sectional studies and no longitudinal finding has been reported. We investigated whether the apolipoprotein E genotype influences baseline and evolution over 4-year follow-up of WML volumes in a population-based sample of 1779 nondemented subjects aged 65 to 80 years old at enrollment. Methods— The sample consisted of 3C-Dijon study participants who had 2 cerebral MRIs, at entry and at 4-year follow-up. WML volumes were estimated using a fully automatic procedure. We performed analysis of covariance to evaluate the relationship between apolipoprotein E genotype and WML load and progression. Results— Multivariable analyses showed that ε4ε4 individuals had both significantly higher WML volume at baseline and higher WML increase over 4-year follow-up than noncarriers and heterozygous of the ε4 allele for apolipoprotein E genotype. Conclusion— These findings suggest it might be important to take into account WML severity when assessing the relationship between apolipoprotein E and dementia.

27 April 2021 in Schizophrenia Bulletin Open
Verified
Journal Article
Open access
PDF file
MLMarion Leboyer
Marion Leboyer
OGOphélia Godin
Ophélia Godin
ETEmilie Terro
Emilie Terro
WBWahid Boukouaci
Wahid Boukouaci
CLChing-Lieng Lu
Ching-Lieng Lu
FBF Berna
F Berna
Treatment-resistant schizophrenia (TRS) affects around 30% of patients with schizophrenia (SZ) resulting in poor functioning, relapses, and reduced quality of life. Convergent findings show that inflammation could contribute to resistance. We thus search for immune signatures of patients with TRS/ultra TRS (UTRS) in a sample of community-dwelling outpatients with SZ. In total, 195 stabilized SZ patients (mean age = 31.2 years, 73% male gender) were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia in France and received a thorough clinical assessment. At inclusion, psychotic symptomatology was evaluated by the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Circulating serum/plasma levels of a large panel of markers reflecting the main inflammatory pathways were evaluated. TRS was defined by current treatment by clozapine (CLZ) and UTRS by current CLZ treatment + PANSS total score ≥ 70. The frequency of TRS and UTRS patients was, respectively, 20% and 7.7% and was defined using multivariable analysis elevated by high levels of interleukin (IL)-12/IL-23p40, IL-17A, IL-10, and beta 2 microglobulin (B2M) and IL-12/IL-23p40, IL-17A, IL-6, IL-10, IFNγ, and B2M, respectively. These observations suggest that resistance and ultra resistance to CLZ treatment are underpinned by pro-inflammatory molecules mainly belonging to the T helper 17 pathway, a finding making sense given the interplay between inflammation and antipsychotic treatment responses. If confirmed, our findings may allow us to consider IL-23/IL-17 pathway as a therapeutic target for patients with resistance to antipsychotics.

12 September 2017 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
CHChantal Henry
Chantal Henry
OGOphelia Godin
Ophelia Godin
PCPhilippe Courtet
Philippe Courtet
JAJean‐Michel Azorin
Jean‐Michel Azorin
SGSébastien Gard
Sébastien Gard
TCThe Face‐Bd Collaborators
The Face‐Bd Collaborators

18 September 2018 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
OGOphélia Godin
Ophélia Godin
MLMarion Leboyer
Marion Leboyer
FSFrank Schürhoff
Frank Schürhoff
PLPierre-Michel Llorca
Pierre-Michel Llorca
Laurent BoyerLaurent Boyer
Laurent Boyer
FGfor the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
for the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
From The Journal of Clinical Psychiatry: Cardiovascular diseases are the primary cause of mortality in individuals with schizophrenia, yet no study has yet explored the impact of metabolic syndrome on schizophrenia relapse. This study explored the effect that several risk factors—including metabolic syndrome—have on schizophrenia relapse.